KURA
New finance boss, same biotech grind
Kura Oncology said Jennifer Fulk is stepping in as Chief Financial Officer, effective September 8th. In biotech, the CFO chair is less about bean-counting and more about survival mode: cash runway, trial spending, and keeping the market calm when the science is still doing the heavy lifting.
Why you should care
A CFO change doesn’t always move the stock on its own, but it can be a meaningful signal. New finance leadership often comes with a reset on capital strategy, investor messaging, and maybe even how aggressively the company spends while it chases its next data readout.
The investor angle
For Kura, this is one of those “watch the tone, not just the title” moments. If Fulk is coming in to sharpen the balance sheet story or prep for future financing, that matters for dilution risk and how much breathing room the company has before the next big catalyst.
Big picture: in biotech, the science gets the headline, but the CFO helps decide whether the story has enough runway to get to the next chapter.